Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Revenue (2016 - 2025)

Cytokinetics (CYTK) has disclosed Revenue for 16 consecutive years, with $86.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue changed N/A to $86.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $156.8 million, a N/A change, with the full-year FY2025 number at $88.0 million, up 333.52% from a year prior.
  • Revenue was $86.5 million for Q4 2025 at Cytokinetics, up from $1.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $89.0 million in Q2 2022 to a low of -$12.7 million in Q2 2024.
  • A 5-year average of $15.9 million and a median of $2.0 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 3029.37% in 2022, then plummeted 1568.51% in 2024.
  • Cytokinetics' Revenue stood at $40.1 million in 2021, then crashed by 95.12% to $2.0 million in 2022, then dropped by 14.56% to $1.7 million in 2023, then crashed by 72.31% to $463000.0 in 2024, then soared by 18580.78% to $86.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Revenue are $86.5 million (Q4 2025), $1.9 million (Q3 2025), and $66.8 million (Q2 2025).